Clinical Gastroenterology and Hepatology
Volume 7, Issue 12 , Pages 1292-1298, December 2009

Comparison of Outcomes Twelve Years After Antireflux Surgery or Omeprazole Maintenance Therapy for Reflux Esophagitis

  • Lars Lundell

      Affiliations

    • Department of Surgery, Karolinska University Hospital, Huddinge, Sweden
    • Corresponding Author InformationReprint requests Address requests for reprints to: Lars Lundell, MD, PhD, Gastrocentrum, Karolinska University Hospital, Huddinge, S-141 86 Stockholm, Sweden. fax: (46) 8-585-823-40
  • ,
  • Pekka Miettinen

      Affiliations

    • Departments of Surgery and Medicine, University Hospital, Kuopio, Finland
  • ,
  • Helge E. Myrvold

      Affiliations

    • Department of Surgery, St Olavs Hospital, NTNU IKM, Trondheim, Norway
  • ,
  • Jan G. Hatlebakk

      Affiliations

    • Department of Surgery, Haukeland University Hospital, Bergen, Norway
  • ,
  • Lene Wallin

      Affiliations

    • Department of Surgery, Glostrup University Hospital, Glostrup, Denmark
  • ,
  • Cecilia Engström

      Affiliations

    • Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
  • ,
  • Risto Julkunen

      Affiliations

    • Departments of Surgery and Medicine, University Hospital, Kuopio, Finland
  • ,
  • Madeline Montgomery

      Affiliations

    • Department of Surgery, Ersta Hospital, Stockholm, Sweden
  • ,
  • Anders Malm

      Affiliations

    • AstraZeneca R & D, Mölndal, Sweden
  • ,
  • Tore Lind

      Affiliations

    • AstraZeneca R & D, Mölndal, Sweden
  • ,
  • Anders Walan

      Affiliations

    • AstraZeneca R & D, Mölndal, Sweden
  • ,
  • The Nordic Gerd Study Group

published online 01 June 2009.

Background & Aims

It is important to evaluate the long-term effects of therapies for gastroesophageal reflux disease (GERD). In a 12-year study, we compared the effects of therapy with omeprazole with those of antireflux surgery.

Methods

This open, parallel group study included 310 patients with esophagitis enrolled from outpatient clinics in Nordic countries. Of the 155 patients randomly assigned to each arm of the study, 154 received omeprazole (1 withdrew before therapy began), and 144 received surgery (11 withdrew before surgery). In patients who remained in remission after treatment, post-fundoplication complaints, other symptoms, and safety variables were assessed.

Results

Of the patients enrolled in the study, 71 who were given omeprazole (46%) and 53 treated with surgery (37%) were followed for a 12-year follow-up period. At this time point, 53% of patients who underwent surgery remained in continuous remission, compared with 45% of patients given omeprazole with a dose adjustment (P = .022) and 40% without dose adjustment (P = .002). In addition, 38% of surgical patients required a change in therapeutic strategy (eg, to medical therapy or another operation), compared with 15% of those on omeprazole. Heartburn and regurgitation were significantly more common in patients given omeprazole, whereas dysphagia, rectal flatulence, and the inability to belch or vomit were significantly more common in surgical patients. The therapies were otherwise well-tolerated.

Conclusions

As long-term therapeutic strategies for chronic GERD, surgery and omeprazole are effective and well-tolerated. Antireflux surgery is superior to omeprazole in controlling overall disease manifestations, but post-fundoplication complaints continue after surgery.

Abbreviations used in this paper: ARS, antireflux surgery, BE, Barrett's esophagus, CI, confidence interval, FDA, Food and Drug Administration, GERD, gastroesophageal reflux disease, GSRS, gastrointestinal symptom rating scale, ITT, intention to treat, OME, omeprazole, PGWB, psychological and general well-being, PPI, proton pump inhibitor, SAE, serious adverse event

 

 This article has an accompanying continuing medical education activity on page 1260. Learning Objectives—At the end of this activity, the learner should be able to understand the effectiveness of long-term medical and surgical therapies for gastroesophageal reflux disease and the long-term side effects of each therapy.

 Conflicts of interest The authors disclose the following: Anders Malm, Tore Lind, and Anders Walan are employed by AstraZeneca. The remaining authors disclose no conflicts.

 Funding This study was funded by AstraZeneca.

PII: S1542-3565(09)00479-0

doi:10.1016/j.cgh.2009.05.021

Refers to article:

  • Exam 1: Comparison of Outcomes Twelve Years After Antireflux Surgery or Omeprazole Maintenance Therapy for Reflux Esophagitis , 02 November 2009

    Mohamad A. Eloubeidi
    Clinical Gastroenterology and Hepatology December 2009 (Vol. 7, Issue 12, Pages 1259-1260)

  • Surgery for Gastroesophageal Reflux Disease: Esophageal Impedance to Progress? , 17 August 2009

    Stuart Jon Spechler
    Clinical Gastroenterology and Hepatology December 2009 (Vol. 7, Issue 12, Pages 1264-1265)

Clinical Gastroenterology and Hepatology
Volume 7, Issue 12 , Pages 1292-1298, December 2009